SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193805-14-002710
Filing Date
2014-12-24
Accepted
2014-12-24 14:04:56
Documents
1
Group Members
DEERFIELD INTERNATIONAL MASTER FUND, L.P.DEERFIELD MANAGEMENT COMPANY, L.P.DEERFIELD MGMT, L.P.DEERFIELD PARTNERS, L.P.DEERFIELD SPECIAL SITUATIONS FUND, L.P.DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 e613199_sc13ga-vanda.htm SC 13G/A 465148
  Complete submission text file 0001193805-14-002710.txt   466753
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Subject) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-82196 | Film No.: 141309880
SIC: 2834 Pharmaceutical Preparations

Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SC 13G/A